Emtricitabine Adjusted

Adjusts emtricitabine dosing according to renal function to ensure safe and effective drug exposure.

mg/dLumol/L
mg/dLumol/L
ml/minml/24hrL/24hr

Indications for Use

Used for HIV treatment as an NRTI backbone combined with tenofovir and for HIV PrEP within TDF/FTC or TAF/FTC regimens (JAMA 2025 1 [Level I evidence]).
Clinically useful for once‑daily dosing, low toxicity, and HBV activity when paired with tenofovir.
Dose adjustment is required in renal impairment because clearance correlates with creatinine clearance (AAC 2014 2 [Level II evidence]).

Insights & Cautions

Use reduced dosing when CrCl <50 mL/min; monitor renal function closely because emtricitabine clearance is directly proportional to creatinine clearance (1 [Level II evidence]).

  • Mild, reversible renal declines occur mainly with TDF‑based combinations, not FTC itself (2 [Level I evidence]).
  • Avoid coadministration with nephrotoxic drugs.
  • GI effects are usually mild; bone effects relate to TDF, not FTC.